Efficacy and safety of aerosolized tobramycin in cystic fibrosis

@article{Pai2001EfficacyAS,
  title={Efficacy and safety of aerosolized tobramycin in cystic fibrosis},
  author={V. Pai and M. Nahata},
  journal={Pediatric Pulmonology},
  year={2001},
  volume={32}
}
  • V. Pai, M. Nahata
  • Published 2001
  • Medicine
  • Pediatric Pulmonology
  • Aerosolized tobramycin has been extensively used in cystic fibrosis (CF) patients in order to directly deliver the antibiotic to the endobronchial site of infection, and decrease toxicity by limiting systemic absorption. Aerosolized tobramycin doses ranging from 80 mg twice or three times daily to 600 mg three times daily have been used in various clinical trials. At an 80‐mg dose, preservation of pulmonary function with little or no improvement over the baseline was reported. Tobramycin… CONTINUE READING
    77 Citations
    Inhalation of tobramycin in patients with cystic fibrosis: comparison of two methods.
    • R. Dopfer, P. Brand, +5 authors R. Siekmeier
    • Medicine
    • Journal of physiology and pharmacology : an official journal of the Polish Physiological Society
    • 2007
    • 17
    • PDF
    Inhaled Tobramycin (TOBI®)
    • 33
    • Highly Influenced
    Renal and vestibular toxicity due to inhaled tobramycin in a lung transplant recipient.
    • V. Ahya, A. Doyle, +7 authors R. Kotloff
    • Medicine
    • The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
    • 2005
    • 25
    Inhaled tobramycin-associated hearing loss in an adolescent with renal failure.
    • 22
    Bronchial Hyperreactivity Related to Inhalation Therapy in Cystic FibrosisPatients
    • 1
    • Highly Influenced
    • PDF